百濟神州(06160.HK)與SEATTLE GENETICS達成先進臨牀前腫瘤候選藥物授權合約
Seattle Genetic (SGEN)是一家新興的多產品、全球性生物技術公司，致力於開發和商業化針對癌症的變革性療法，以在人們的生活中產生有意義的變化。百濟神州(06160.HK)是一家處於商業階段的生物醫藥公司，專注於用於癌症治療的創新性分子靶向和免疫腫瘤藥物的開發和商業化。兩家公司於2019年11月5日宣佈雙方就一款先進的臨牀前腫瘤候選藥物達成授權合約。該候選藥物運用Seattle Genetic專利保護的抗體技術，預計將於2020年上半年進入臨牀試驗階段。
根據合作條款，Seattle Genetic將保留該候選藥物在美洲(美國、加拿大以及拉丁美洲國家)、歐洲以及日本的權利，百濟神州獲得在亞洲(除日本以外)以及世界其他國家的獨家開發與商業化權利。Seattle Genetic將帶領在全球範圍內的開發，而百濟神州將負責為上述所屬國家和地區範圍內開展的臨牀試驗提供資金並開展運營。百濟神州還將負責在上述所屬國家和地區的臨牀開發以及註冊申報。Seattle Genetic將獲得授權許可首付款，並有資格獲得至多1.6億美元的取決於進展的里程碑付款以及任何產品銷售的分級特許使用費。
Seattle Genetic首席醫學官Roger Dansey醫學博士評論道：“與百濟神州就此候選藥物開展合作，有可能加速其在全球以及幾個關鍵地區的進程，特別是在抗癌藥物方面有未被滿足的醫療需求的中國。百濟神州專注於創新型靶向抗癌藥物的開發，也為此次合作注入其強大的臨牀開發以及商業運營能力。我們期待共同合作，為全世界各地的患者開發這款藥物。”
百濟神州高級副總裁，全球研究、臨牀運營與生物統計暨亞太臨牀開發負責人汪來博士表明：“Seattle Genetic以其富有變革性的腫瘤學發現在業界得到認可，我們很高興能就這款新候選藥物的全球發展開展合作。此項合作與我們公司的使命緊密相連－我們致力於開展世界級的臨牀開發和商業化，為世界各地的患者帶來有意義的創新型新藥。我們在全球範圍內已開展了60多項臨牀試驗，而這項即將開始的全球臨牀試驗也將為我們廣泛的抗腫瘤專案帶來一款新的候選藥物。”
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
